|本期目录/Table of Contents|

[1]李泽宇,张冠英,张春锋,等.高危非肌层浸润性膀胱癌术后行膀胱热灌注化疗和卡介苗灌注治疗的对比研究[J].天津医科大学学报,2024,30(04):328-331,370.[doi:10.20135/j.issn.1006-8147.2024.04.0328]
　LI Zeyu,ZHANG Guanying,ZHANG Chunfeng,et al.A comparative study of hyperthermic intravesical chemotherapy and Bacillus Calmette Guerin intravesical chemotherapy for high-risk non-muscular invasive bladder cancer after surgery[J].Journal of Tianjin Medical University,2024,30(04):328-331,370.[doi:10.20135/j.issn.1006-8147.2024.04.0328]
点击复制

高危非肌层浸润性膀胱癌术后行膀胱热灌注化疗和卡介苗灌注治疗的对比研究(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
30卷
期数:
2024年04期
页码:
328-331,370
栏目:
肿瘤疾病专题
出版日期:
2024-07-10

文章信息/Info

Title:
A comparative study of hyperthermic intravesical chemotherapy and Bacillus Calmette Guerin intravesical chemotherapy for high-risk non-muscular invasive bladder cancer after surgery
文章编号:
1006-8147(2024)044-0328-05
作者:
李泽宇; 张冠英; 张春锋; 宋伟航; 何岩
（新乡医学院第一附属医院泌尿外科二病区，卫辉 453100）
Author(s):
LI Zeyu; ZHANG Guanying; ZHANG Chunfeng; SONG Weihang; HE Yan
（Urology Department 2 of the First Affiliated Hospital of Xinxiang Medical University，Weihui 453100，China）
关键词:
膀胱癌; 膀胱热灌注化疗; 卡介苗; 吉西他滨
Keywords:
bladder cancer; hyperthermic intravesical chemotherapy; BCG; gemcitabine
分类号:
R699.5
DOI:
10.20135/j.issn.1006-8147.2024.04.0328
文献标志码:
A
摘要:
目的：探讨膀胱热灌注化疗和卡介苗（BCG）膀胱灌注预防高危非肌层浸润性膀胱癌患者术后复发的安全性和有效性。方法：回顾性分析2019年8月—2021年8月在新乡医学院第一附属医院行经尿道膀胱肿瘤电切术，且术后行吉西他滨膀胱热灌注化疗（HIVEC-GEM）或BCG膀胱灌注的高危非肌层浸润性膀胱癌患者资料共74例，其中38例行HIVEC-GEM膀胱灌注（HIVEC-GEM组），36例行BCG膀胱灌注（BCG组），比较两组术后肿瘤复发率和进展率以及不良反应发生率。结果：两组术后6个月的复发率（5.26% vs. 2.78%，χ2=0.002）和进展率（5.26% vs. 2.78%，χ2=0.002）、术后12个月的复发率（13.16% vs. 8.33%，χ2=0.086）和进展率（10.53% vs.8.33%，χ2=0.006）以及术后24个月的复发率（18.42% vs. 13.89%，χ2=0.279）和进展率（13.16% vs. 11.11%，χ2=0.007）差异均无统计学意义（均P＞0.05），多种不良反应发生率之间的比较也无统计学意义（均P＞0.05）。结论：HIVEC-GEM的疗效和安全性与BCG膀胱灌注相当。
Abstract:
Objective： To explore the safety and effectiveness of hyperthermic intravesical chemotherapy（HIVEC） and Bacillus Calmette Guerin（BCG） intravesical chemotherapy in preventing the postoperative recurrence of high-risk non-muscle invasive bladder cancer. Methods：This study retrospectively analyzed the clinical data of patients with high-risk non-muscle invasive bladder cancer who underwent transurethral resection of bladder tumor（TURBT） in the Frist Affiliated Hospital of Xinxiang Medical College from August 2019 to August 2021. These patients received postoperative hyperthermic intravesical chemotherapy with gemcitabine（HIVEC-GEM） or BCG intravesical chemotherapy. A total of 74 patients，with 38 undergoing HIVEC-GEM and 36 undergoing BCG therapy，were divided into the HIVEC-GEM group and the BCG group. The groups were compared based on the recurrence rate and progression rate of the tumor，as well as the incidence of adverse events. Results：The recurrence rates at 6 months（5.26% vs. 2.78%，χ2=0.002） and 12 months（13.16% vs. 8.33%，χ2=0.086） post-surgery，as well as the progression rates at 6 months（5.26% vs. 2.78%，χ2=0.002），12 months（10.53% vs. 8.33%，χ2=0.006），and 24 months（13.16% vs. 11.11%，χ2=0.086） post-surgery，showed no significant difference between the two groups（all P>0.05）. Additionally，there was no statistical significance in the incidence of multiple adverse events（all P>0.05）. Conclusion：The efficacy and safety of HIVEC-GEM are comparable to those of BCG therapy.

参考文献/References:

[1] FERLAY J，SOERJOMATARAM I，DIKSHIT R，et al. Cancer incidence and mortality worldwide： sources，methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer，2015，136（5）：E359–E386.
[2] KAFKASLI A，YAZICI O，CAN U，et al.Testosterone status is not associated with bladder cancer parameters in adult male patients： results of a prospective controlled study[J]. Aging Male，2021，24（1）：101-105.
[3] GONTERO P，SYLVESTER R，PISANO F，et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin： results of a retrospective multicenter study of 2451 patients[J].Eur Urol，2015， 67（1）：74-82.
[4] BABJUK M，BURGER M，CAPOUN O，et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer （Ta，T1，and carcinoma in situ）[J].Eur Urol，2022，81（1）：75-94.
[5] PLATA A，GUERRERO-RAMOS F，GARCIA C，et al. Long-term experience with hyperthermic chemotherapy（HIVEC） using mitomycin-c in patients with non-muscle invasive bladder cancer in Spain[J]. J Clin Med，2021，10（21）：5105.
[6] PAZIR Y，ESMERAY A，CAGLAR U，et al. Comparison of hyperthermic intravesical chemotherapy and bacillus calmette-guerin therapy in high-risk non-muscle invasive bladder cancer： a matched-pair analysis[J]. Int Urol Nephrol，2024，56（3）：957-963.
[7] SIKIC D，TAUBERT H，WIRTZ R M，et al. High androgen receptor mrna expression is associated with improved outcome in patients with high-risk non-muscle-invasive bladder cancer[J]. Life （Basel），2021，11（7）：642.
[8] DI STASI S M，GIANNANTONI A，GIURIOLI A，et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer： a randomised controlled trial[J]. Lancet Oncol，2006，7（1）：43-51.
[9] BERGER A P，STEINER H，STENZL A，et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer： a single-center study[J].Urology，2003，61（2）：338-341.
[10] ARENDS T J，NATIV O，MAFFEZZINI M，et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin c versus bacillus calmette-guérin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer[J]. Eur Urol，2016，69（6）：1046-1052.
[11] LONGO T A，GOPALAKRISHNA A，TSIVIAN M，et al. A systematic review of regional hyperthermia therapy in bladder cancer[J]. Int J Hyperthermia，2016，32（4）：381-389.
[12] ARRABAL POLO M ?魣，MELGAREJO SEGURA M T，Y?魣?譙EZ CAST- ILLO Y，et al. Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study[J]. J Cancer Res Clin Oncol，2023， 149（10）：7453-7459.
[13] EFILO■LU ■，BAYRAK ■，TURAN T，et al. Thermal intravesical chemotherapy in adjuvant treatment of high risk non-muscle invasive bladder cancer[J].Arch Esp Urol，2021，74（9）：875-882.
[14] FREY B，WEISS E M，RUBNER Y，et al. Old and new facts about hyperthermia-induced modulations of the immune system[J]. Int J Hyperthermia，2012；28（6）：528-542.
[15] GILL R S，AL-ADRA D P，NAGENDRAN J，et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC： a systematic review of survival，mortality，and morbidity[J]. J Surg Oncol，2011，104（6）：692-698.
[16] MAGALH?魨ES J C，SOUSA M，BASTO R，et al. Adjuvant hyperthermic intravesical chemotherapy in intermediate- and high-risk non-muscle invasive bladder cancer[J]. Cureus，2023，15（9）：e45672.
[17] GUERRERO-RAMOS F，GONZ?魣LEZ-PADILLA D A，GONZ?魣-LEZ-D?魱AZ A，et al. Recirculating hyperthermic intravesical chemo-therapy with mitomycin C （HIVEC） versus BCG in high-risk non-muscle-invasive bladder cancer： results of the HIVEC-HR randomized clinical trial[J]. World J Urol，2022，40（4）：999-1004.
[18] LUO J，GUO L，CHEN L，et al. Efficacy and safety of HIVEC versus ETFT in non-muscle-invasive bladder cancer： a systematic review and meta-analysis[J]. Asian J Surg，2024，47（1）：665-668.
[19] PIGNOT G，BABOUDJIAN M，LEBACLE C，et al. Efficacy of hyperthermic intravesical chemotherapy（HIVEC） in patients with non-muscle invasive bladder cancer after BCG failure[J].World J Urol，2023，41（11）：3195-3203.
[20] CERRATO C，ROUPRET M，MIR M C. Results from HIVEC-Ⅱfor intermediate-risk non-muscle-invasive bladder cancer： is this a dead end for mitomycin C hyperthermia[J].Eur Urol，2023；83（6）：505-507.

相似文献/References:

[1]陈可新,郝晓东,薄志强,等.≤pT2N0M0膀胱癌根治术后近期复发的影响因素分析[J].天津医科大学学报,2017,23(04):357.
　CHEN Ke-xin,HAO Xiao-dong,BO Zhi-qiang,et al.Influencing factors and prognosis of short-term relapse after radical cystectomy of primary bladder cancer（≤pT2N0M0）[J].Journal of Tianjin Medical University,2017,23(04):357.
[2]孟旭英,李珍瑾,郭剑超.组蛋白甲基转移酶EZH2抑制剂联合抗癌药物对膀胱癌细胞功能影响的研究[J].天津医科大学学报,2018,24(01):25.
　MENG Xu-ying,LI Zhen-jin,GUO Jian-chao.Effect of histone methyltransferase EZH2 inhibitor combined with anticancer drugs on migration and proliferation of bladder cancer cells[J].Journal of Tianjin Medical University,2018,24(04):25.
[3]刘 莉 康家旗 综 述,刘晓强 审 校.膀胱癌外周血生物标志物研究进展[J].天津医科大学学报,2018,24(06):566.
[4]刘志飞,张志宏,邢力永,等.RRM1 mRNA与吉西他滨药物膀胱灌注治疗膀胱癌疗效的关系[J].天津医科大学学报,2019,25(01):51.
　LIU Zhi-fei,ZHANG Zhi-hong,XING Li-yong,et al.The relationship between expression of RRM1 mRNA and efficacy of intravesical of gemcitabine in patients with nonmuscle-insive bladder caner[J].Journal of Tianjin Medical University,2019,25(04):51.
[5]付真睿,盛 飞,张昌文,等.SOX6在膀胱癌发生发展中的作用及相关机制[J].天津医科大学学报,2019,25(04):373.
　FU Zhen-rui,SHENG Fei,ZHANG Chang-wen,et al.The characteristics of SOX6 in development of bladder cancer and relevant mechanism[J].Journal of Tianjin Medical University,2019,25(04):373.
[6]王银蕾,杨 瀚,高 杰,等.PITX2启动子甲基化及其与膀胱癌临床病理的关系[J].天津医科大学学报,2020,26(01):39.
　WANG Yin-lei,YANG Han,GAO Jie,et al.Methylation of PITX2 promoter and relationship with clinical pathology of bladder cancer[J].Journal of Tianjin Medical University,2020,26(04):39.
[7]王玉杰,沈冲,高深,等.长链非编码RNA-FENDRR在膀胱癌组织中的表达及临床意义[J].天津医科大学学报,2020,26(05):445.
　WANG Yu-jie,SHEN Chong,GAO Shen,et al.Expression of long non-coding RNA FENDRR in human bladder cancer tissues and Clinical significance[J].Journal of Tianjin Medical University,2020,26(04):445.
[8]朱建强,郑志文,付青峰,等.人工纳米材料在膀胱癌诊疗中的研究进展[J].天津医科大学学报,2022,28(05):563.
[9]陆益,于佳熙,梁政.氯丙嗪对膀胱癌BT-B细胞迁移功能的影响[J].天津医科大学学报,2022,28(06):621.
　LU Yi,YU Jia-xi,LIANG Zheng.The effect of chlorpromazine on the migration of BT-B cellsin bladder cancer[J].Journal of Tianjin Medical University,2022,28(04):621.
[10]孙晓宇 张志宏 张昌文.膀胱癌类器官模型的研究进展[J].天津医科大学学报,2023,29(05):564.

备注/Memo

备注/Memo:
作者简介：李泽宇（1987-），男，主治医师，硕士，研究方向：泌尿系统肿瘤及前列腺疾病；
通信作者：何岩，E-mail：Heyan497@sohu.com。
更新日期/Last Update: 2024-07-10